Tasquinimod
An immunomodulator with a unique mechanism of action for myelofibrosisIn development for the treatment of hematological malignancies. Clinical phase I/II studies in myelofibrosis are ongoing.
Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition (HOVON 172 MF)
Clinical StudiesThe European study is being conducted within the HOVON research network (Stichting Hemato-Oncologie voor Volwassenen Nederland), with participating clinics in the Netherlands and Germany.
Pipeline
Discovery
Preclinical
Phase I
Phase II
Phase III
Tasquinimod – Myelofibrosis
Partners: HOVONEurope
In July 2023, Active Biotech entered into an agreement between the Oncode Institute, Erasmus MC and Stichting-Haemato-Oncologie Volwassenen Netherlands (HOVON) for a clinical study in myelofibrosis. HOVON is one of the leading European clinical study groups in hematological malignancies and is the legal sponsor of the study. The study has been actively recruiting patients since January 2025 and aims to include up to 20 patients.
The title of the study is “Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition” (HOVON 172 MF), and it evaluates tasquinimod as monotherapy in patients with myelofibrosis who have previously been treated with a JAKi or who are not suitable for treatment with JAKi. In addition to safety and tolerability, the study will examine the effect of tasquinimod on the disease by measuring changes in clinically relevant variables including spleen volume, symptom control and bone marrow fibrosis grade.
For more information about the study, visit clinicaltrials.gov (NCT06605586)
Facts about the Study
Status:
Ongoing - Phase I/II
Partners:
HOVONEurope
Study ID:
NCT06605586